Results 81 to 90 of about 85,863 (235)

A Delphi consensus project to capture experts' opinion on hyperkalaemia management across the cardiorenal spectrum

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1132-1140, April 2025.
Abstract The main purpose of this project was to capture experts' opinion on hyperkalaemia management and form best practice recommendations for cardiorenal patients in Greece. A steering committee of nephrologists and cardiologists developed 37 statements. An online questionnaire completed by 32 experts in cardiorenal management in Greece.
Christina Chrysohoou   +3 more
wiley   +1 more source

A logistic regression model for microalbuminuria prediction in overweight male population [PDF]

open access: yes, 2010
Background: Obesity promotes progression to microalbuminuria and increases the risk of chronic kidney disease. Current protocols of screening microalbuminuria are not recommended for the overweight or obese. Design and Methods: A cross-
BaoDe Chen   +5 more
core   +1 more source

RELATION OF ALBUMINURIA TO INDICANURIA [PDF]

open access: yesJournal of the American Medical Association, 1912
From the records of 500 specimens of urine examined in the clinical laboratories of the Medico-Chirurgical and Jewish Hospitals, during 1909 and 1910, including specimens from my own practice examined in my office, I find an apparent definite relationship existing between the occurrence of albumin and indican.
openaire   +2 more sources

Clinical utility and safety of finerenone in patients with heart failure: Rationale and design of FINE registry

open access: yesESC Heart Failure, EarlyView.
Abstract Aims Information about current use of finerenone in patients with heart failure (HF) finerenone in clinical practice is scarce, and its effectiveness in clinical practice in patients is scarce. We aim to assess both the baseline clinical profile and prognostic role of finerenone in patients with HF, irrespective of ejection fraction.
Gonzalo Luis Alonso Salinas   +32 more
wiley   +1 more source

SGLT2 inhibitor with and without ALDosterone AntagonIst for heart failure with preserved ejection fraction: Design paper

open access: yesESC Heart Failure, EarlyView.
Abstract Background Sodium glucose co‐transporter 2 inhibitors (SGLT2i) and mineralocorticoid receptor antagonists (MRA) reduce heart failure (HF) events in patients with heart failure and mildly reduced or preserved ejection fraction (HFmr/pEF). The randomized comparison of SGLT2i/MRA combination versus SGLT2i or MRA alone requires further testing in ...
João Pedro Ferreira   +26 more
wiley   +1 more source

Longest survivor of pulmonary atresia with ventricular septal defect without surgical intervention

open access: yes
ESC Heart Failure, Volume 12, Issue 2, Page 1499-1507, April 2025.
Sang Zhou   +5 more
wiley   +1 more source

METAB‐HTX: prospective, longitudinal cohort study evaluating cardiac and systemic metabolism after heart transplantation

open access: yesESC Heart Failure, EarlyView.
The METAB‐HTX trial is a prospective cohort study, evaluating cardiac and systemic metabolism among heart transplant recipients. Myocardial function, energetic and metabolism, allograft vasculopathy, allograft rejection, glucometabolism, lipometabolism, liver‐ and kidney function, leucocyte signatures and thromboinflammation will be evaluated ...
Amin Polzin   +21 more
wiley   +1 more source

Canagliflozin reduces oral loop diuretic intensification in patients with type 2 diabetes: A participant‐level pooled analysis of the CANVAS and CREDENCE trials

open access: yesEuropean Journal of Heart Failure, EarlyView.
Among high‐risk patients with T2D, new oral loop diuretic intensification was frequent and portended adverse prognostic significance. Treatment with canagliflozin significantly reduced the need for loop diuretic intensification. ABSTRACT Aims The sodium–glucose cotransporter 2 inhibitor canagliflozin reduces the risk of heart failure (HF ...
Safia Chatur   +11 more
wiley   +1 more source

Home - About - Disclaimer - Privacy